Common Joint Supplement Glucosamine Linked to Faster Alzheimer’s Progression

A recent study conducted by the University of Florida suggests that glucosamine, a widely used over-the-counter supplement for joint pain, may be associated with an accelerated progression of Alzheimer’s disease. By analyzing health records from over 4,600 patients with mild cognitive impairment (MCI) or Alzheimer’s disease and related dementias (ADRD), researchers identified a 25% higher likelihood of transitioning to dementia among those who regularly used the supplement. Furthermore, the study noted a 25% increase in mortality risk for patients already diagnosed with ADRD who took glucosamine.

While the study does not definitively prove that glucosamine causes dementia, the findings highlight a critical intersection between metabolic health and neurodegeneration. The research team, utilizing artificial intelligence to parse over a decade of patient data, discovered that glucosamine may interfere with specific biological pathways already compromised in the brains of Alzheimer’s patients. Specifically, the researchers observed that a protein and sugar-tagging pathway becomes hyperactive during the disease process, and the supplement appears to exacerbate this metabolic dysfunction.

This research carries significant implications for the millions of older adults who rely on supplements to manage chronic pain. Because glucosamine is easily accessible and frequently used without medical supervision, these findings suggest an urgent need for further clinical trials to clarify the risks. Beyond the immediate safety concerns, the study underscores the growing importance of metabolic health in neurodegenerative research, suggesting that future therapeutic strategies should look beyond traditional plaque-and-tangle approaches to address the underlying metabolic defects driving cognitive decline.